Name: UMIN ID:
Unique ID issued by UMIN | UMIN000013467 |
---|---|
Receipt number | R000015621 |
Scientific Title | Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myeloma |
Date of disclosure of the study information | 2014/03/20 |
Last modified on | 2020/01/04 01:11:57 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/03/19 19:02:01 | ||
2 | Update | 2020/01/04 01:09:09 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Organization Email3 Organization Organization Address Address Tel |
|
3 | Update | 2020/01/04 01:10:30 | Recruitment status Date of IRB Last follow-up date |
|
4 | Update | 2020/01/04 01:11:39 | Last follow-up date |
|
5 | Update | 2020/01/04 01:11:57 | Number of participants that the trial has enrolled |